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A B S T R A C T
We investigated the influence of alpha-melanocyte stimulating hormone (a-MSH) on the healing of corneal epithelial
lesions in male Wistar rats. The lesions were induced by abrading corneal epithelium with a surgical lancet under a
biomicroscope. Before the abrasion corneal epithelium was softened with 40% ethanol. a-MSH drops in a concentration
of 1×10–4 mg/mL significantly promoted epithelial healing, when compared to the control group treated with 0.9% NaCl.
Significant reduction of ocular irritation was also observed. Topical a-MSH medication could promote the healing of
corneal wounds and reduce local inflammatory response without the major side effects of the corticosteroid therapy.
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Introduction
Alpha-melanocyte stimulating hormone (a-MSH) is a
peptide deriving from the post-translational processing
of the pro-opiomelanocortin (POMC) molecule1,2. The
POMC prohormone gives rise to a variety of biologically
active peptides including adrenocorticotropin (ACTH)
and a-MSH1,2. a-MSH corresponds to the first 13 amino
acids of the ACTH sequence. A synthetic peptide frag-
ment of ACTH4–10 has been shown to improve the rabbit
cornea wound healing3.
Other results indicated that in addition to strong
anti-inflammatory and cytoprotective effects on different
organs and tissues a-MSH elicits antimicrobial and anti-
fungal effects1,2,4,5.
Impaired and prolonged reepithelization of corneal le-
sions may result in long lasting corneal defects, which
can possibly be followed by serious complications such as
microbial and fungal inflammation and corneal opaci-
fication. Therefore, we have investigated the effects of
a-MSH on the corneal healing and reduction of eye irri-
tation caused by the abrasion of rat corneal epithelium.
Materials and Methods
Animals
Wistar male albino rats weighing from 160 to 180 g
were used as the experimental animals. They were kept
under standard conditions with a 12 hour light/dark cy-
cle. The rats were divided in groups of 6 animals and a
control group had 8 animals.
Corneal abrasion
Standardized 3 mm wide circular lesions were in-
duced by abrading corneal epithelium with a surgical
lancet under a hand-held biomicroscope (Heine HSL
100)6. Before scraping the cornea, epithelium was soft-
ened with a circular filter paper soaked in 40% ethanol,
placed on cornea for 30 seconds and irrigated with saline
solution. Abrasion procedure was done in light ether an-
esthesia (Narkosaether, Lek, Slovenia). Immediately af-
ter the abrasion, corneas were dyed with a sterile fluores-
cein solution. High resolution digital camera (Panasonic
NV-GX7, 1200000 pixels) was used to make the photo-
graphs of abraded corneas under a cobalt blue UV lamp
at 0, 2, 8, 16 and 24 hour intervals.
Treatment protocol
Corneal lesions were treated with two eye drops of
a-MSH (SYSMEHFRWGKPV, >97% purity7 administer-
ed in 10 seconds intervals, at 0, 2, 8 and 16 hours after
the injury. The following eye drop concentrations were
used: 1 mg/mL, 1×10–1 mg/mL, 1×10–2 mg/mL, 1×10–3
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mg/mL, 1×10–4 mg/mL. The control group was treated
with 0.9% NaCl (1 drop = 0.05 mL).
Evaluation and scoring of corneal lesions
and ocular irritation
The healing of corneal lesions was scored after the ini-
tial abrasion using a modified Draize test6,8. Originally,
Draize test is used to score the advancement of a lesion
after application of an irritant. In this experiment we
have reversed the method. The score was calculated as
follows: score 0 for no corneal lesion detected, score 1 for
0–25%, score 2 for 25–50%, score 3 for 50–75% and score
4 for 75–100% of initial lesion surface still not healed.
The relative size of each lesion was compared to the
whole surface of the cornea using image processing soft-
ware (ImageJ). The intensity of conjunctival irritation
was described by numbers, from 1 (for a minimal) to 10
(for a maximal irritation as seen in saline treated eyes).
The mean of the left and right eye score was used.
Data analysis
Statistical analysis and comparison of control and
treated groups was performed with Steel’s test – a non-
parametric version of Dunett’s test. The analysis was
made by using KyPlot software (version 4.0) and Graph-
Pad Prism software (version 5.0).
Results
Five groups of experimental animals were treated
with a-MSH drops in the following range of concentra-
tions: 1 mg/mL, 1×10–1 mg/mL, 1×10–2 mg/mL, 1×10–3
mg/mL and 1×10–4 mg/mL. The control group was treat-
ed with 0.9% NaCl drops.
a-MSH concentrations in the range from 1 mg/1 mL
to 1?10–3 mg/mL did not significantly affect the rate of
corneal healing (Table 1). The peptide concentration of
1×10–4 mg/mL significantly promoted epithelial healing
in rat corneas when compared to the control group, 16
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TABLE 1
EFFECTS OF DIFFERENT CONCENTRATIONS OF a-MSH ON THE HEALING OF CORNEAL EPITHELIAL DEFECTS 2, 8, 16 AND 24
HOURS AFTER ABRASION (DESCRIPTIVE STATISTICS)
Control (0.9% NaCl) N X Median Min Max Q1 Q3 SD Steel test
2 h 8 99.8 101.4 60.6 140.6 87.1 109.9 24.2
8 h 8 68.9 70.1 22.3 92.6 65.0 83.0 21.5
16 h 8 43.7 38.2 16.8 84.0 29.3 56.9 22.6
24 h 8 16.3 14.0 2.7 49.0 7.6 17.9 14.2
Alpha-MSH (1×10–4 mg/mL) N X Median Min Max Q1 Q3 SD p value
2 h 6 75.7 72.5 53.4 110.5 70.6 74.8 18.8 0.608
8 h 6 62.1 57.4 52.1 89.6 52.4 63.5 14.4 >0.999
16 h 6 10.4 5.8 3.5 25.2 4.5 17.45 8.9 0.008
24 h 6 0.1 0.0 0.0 0.6 0.3 0.6 0.2 0.007
Alpha-MSH (1×10–3 mg/mL) N X Median Min Max Q1 Q3 SD p value
2 h 6 78.5 78.8 58.8 99.6 68.1 86.7 14.2 >0.999
8 h 6 66.9 70.9 42.7 85.3 56.4 75.3 15.3 >0.999
16 h 6 24.9 23.5 7.6 42.1 10.1 38.5 14.2 >0.999
24 h 6 1.2 0.0 0.0 5.2 0.00 3.7 2.1 0.001
Alpha-MSH (1×10–2 mg/mL) N X Median Min Max Q1 Q3 SD p value
2 h 6 85.4 85.8 69.4 103.5 76.4 91.4 12.1 >0.999
8 h 6 57.0 58.2 43.3 68.4 51.9 62.2 8.7 >0.999
16 h 6 20.2 19.8 8.2 36.8 8.5 27.9 11.1 0.695
24 h 6 13.4 10.7 3.9 31.1 5.1 24.5 9.9 0.996
Alpha-MSH (1×10–1 mg/mL) N X Median Min Max Q1 Q3 SD p value
2 h 6 88.3 93.0 65.7 102.9 72.3 102.8 16.3 >0.999
8 h 6 73.3 77.2 45.0 92.0 61.2 87.1 17.5 >0.999
16 h 6 31.0 29.6 10.6 50.8 18.3 47.3 16.6 >0.999
24 h 6 19.5 19.4 0.0 42.0 4.5 34.6 14.6 0.996
Alpha-MSH (1mg/mL) N X Median Min Max Q1 Q3 SD p values
2 h 6 9.0 113.8 73.4 138.1 95.3 119.7 22.2 >0.999
8 h 6 75.7 77.9 50.6 91.1 74.5 82.1 13.7 >0.999
16 h 6 24.6 24.3 13.9 41.3 14.9 28.8 10.2 >0.999
24 h 6 17.3 18.7 5.2 25.6 7.8 25.4 8.2 0.853
Alpha-MSH – alpha-melanocyte stimulating hormone
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and 24 hours after epithelial abrasion (Table 1, Figure 1).
a-MSH concentration of 1×10–3 mg/mL was also effec-
tive 24 hours after epithelial abrasion (Table 1, Figure 1).
Compared to the animals treated with 0.9% NaCl drops
a-MSH drops elicited a significant reduction of conjunc-
tival hyperemia in all treated groups 16 hours after cor-
neal abrasion (p<0.05, Table 2, Figure 2).
Discussion
Integrity of ocular surface epithelium and corneal
re-epithelization is vital for normal hydration and trans-
parency of the cornea. It may therefore have influence on
visual function and present a key process in prevention
of corneal and intraocular infection9. During the healing
process the migration and proliferation of the corneal ep-
ithelium takes place. Simultaneously, activation of differ-
ent growth factors as well as some cytokines occurs as
part of an inflammatory reaction10. Inflammatory and
immunological reactions inside the cornea may cause fi-
brosis which could subsequently reduce corneal trans-
parency and lead to blindness. Corticosteroids applied lo-
cally have a beneficial effect on fibrosis prevention after
injury. However, they also inhibit wound healing and
thus can not be used until the integrity of the ocular sur-
face is re-established. Moreover, they have a number of
known side effects such as ocular hypertension, glau-
coma, cataract formation, epithelial toxicity, crystalline
keratopathy, decreased wound strength and therefore
they should be applied very cautiously11,12.
Although several substances have been reported to
improve the corneal healing rate6,12, it is still necessary
to search for substances that could facilitate corneal
re-epithelization and prevent fibrosis at the same time.
Besides the observed beneficial effects on corneal epithe-
lization and irritation, a-MSH is known to play an im-
portant role as a mediator of immunoregulatory and
immunosuppressory processes which occur in the aque-
ous humor13. In anti-inflammatory reactions a-MSH is
involved by suppression of prostaglandin E2 (PGE2), tu-
mor necrosis factor-a (TNF-a), interleukin-1 (IL-1), in-
terleukin-6 (IL-6) and monocyte chemotactic protein-1
(MCP-1) production as well as by blocking cyclo-oxy-
genase-2 (COX-2) expression14. Furthermore, it may also
be useful as an anti-inflammatory agent in ocular trau-
ma treatment maintaining blood-aqueous barrier integ-
rity as opposed to steroids14. After penetrating corneo-
limbal cut systemic and topical treatment with a-MSH in
rabbits equal or better results in reducing intraocular in-
flammatory reactions compared to topical application of
corticosteroids were shown15. In the same animal model
its hypotensive ocular effect with sustained reduction of
intraocular pressure after a single topical application
was also established16. Moreover, the local subconjunc-
tival treatment with a-MSH reduced allorejection of rat
corneal grafts17.
































































































Fig. 1. Healing of corneal defects – percentage of the
initial lesion after 24 hours. a-MSH – alpha-melanocyte
stimulating hormone.
TABLE 2
EFFECTS OF a-MSH ON OCULAR IRRITATION 16 HOURS AFTER
EPITHELIAL ABRASION (INTENSITY SCORE FROM 1 FOR
MINIMAL TO 10 FOR MAXIMAL CONJUNCTIVAL HYPEREMIA)
Substance X SD Median
Steel
test (p)
Control 0.9% NaCl 9.7 1.22 10.0
a-MSH 1 mg/mL 4.7 1.50 4.0 0.007
a-MSH 1×10–4 mg/mL 5.2 1.47 5.5 0.007
a-MSH 1×10–3 mg/mL 3.5 0.55 3.5 0.006
a-MSH 1×10–2 mg/mL 5.2 0.98 5.5 0.007
a-MSH 1×10–1 mg/mL 5.0 1.27 4.5 0.007






















































































Fig. 2. Ocular irritation in a-MSH treated groups and con-
trols 16 hours after epithelial abrasion. a-MSH – alpha-melano-
cyte stimulating hormone.
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Our investigation demonstrates that topical applica-
tion of a-MSH could facilitate hyperemia and promote
re-epitelization of the cornea in rats without significant
side effects. However, the influence on the corneal epi-
thelium healing was dose dependent with observed sta-
tistically significant influence at a concentration of
1×10–4 mg/mL of a-MSH. This is in accordance with the
fact that a-MSH induced ocular hypotensive effect is also
dose dependent15,16 just as its activity in the nervous
system18, skin19 and its influence as an anti-inflamma-
tory agent20. The favorable hypotensive effect of a-MSH
on intraocular pressure was achieved with aqueous phys-
iological doses (10–8M – 10–9M)15. Our results are consis-
tent with the data of Naveh et al.15,16 since we observed
that two most efficient doses with respect to the corneal
wound healing ranged from 6×10–8M (1×10–3 mg/mL) to
6×10–9 M (1×10–4 mg/mL). In some previous studies
a-MSH was used in higher non-physiological doses caus-
ing flare and increased values of intraocular pressure af-
ter its application21,22. Considering that these values
were far greater than the physiological it is reasonable to
conclude that we could benefit only if the doses close to
the physiological ones in the aqueous humor are ap-
plied15,16. The possible topical application of a-MSH
could provide an advantage when compared to some
long-established but more aggressive methods that have
proven to facilitate corneal epithelial healing23.
In summary, we have demonstrated that topical a-
-MSH medication could promote the healing of corneal
wounds and simultaneously reduce the inflammatory re-
sponse without the major side effects of corticosteroid
therapy. Further studies are therefore necessary to de-
termine the most effective doses with the longest and
most permanent outcome with minimal relapses. Thus
we can suggest that a-MSH could be considered as a pos-
sible future therapy for corneal defects.
Conclusions
a-MSH concentration of 1×10–4 mg/mL significantly
promoted epithelial healing in rat corneas when com-
pared to the control group, at 16 hours and 24 after epi-
thelial abrasion.
Compared to the animals treated with with 0.9%
NaCl, a-MSH drops elicited a significant reduction of oc-
ular irritation in all treated groups 16 hours after corneal
abrasion.
Topical a-MSH medication promotes the healing of
corneal wounds and reduces local irritation and inflam-
mation.
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DJELOVANJE a-MSH NA O[TE]ENJA EPITELA RO@NICE U [TAKORA
S A @ E T A K
Istra`ivali smo utjecaj alfa-melanostimuliraju}eg hormona (a-MSH) na cijeljenje epitelnih o{te}enja ro`nice u mu`-
jaka Wistar {takora. Lezije su izazvane abrazijom epitela ro`nice kirur{kom lancetom pod kontrolom biomikroskopa.
Prije abrazije epitel je omek{an djelovanjem 40% etanola. Primjena a-MSH kapi u koncentraciji od 1×10–4 mg/mL
zna~ajno pospje{uje cijeljenje epitela u usporedbi s kontrolnom grupom lije~enom kapima 0,9% NaCl uz zna~ajno sma-
njenje hiperemije oka. Lokalna primjena a-MSH mo`e pospje{iti cijeljenje rana ro`nice uz smanjenje lokalnog upalnog
odgovora bez izra`enijih nuspojava kortikosteroidne terapije.
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